Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis.

Goncharova EA, Goncharov DA, Damera G, Tliba O, Amrani Y, Panettieri RA Jr, Krymskaya VP.

Mol Pharmacol. 2009 Oct;76(4):766-77. doi: 10.1124/mol.109.057042. Epub 2009 Jul 13.

2.

Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.

Goncharova EA, Goncharov DA, Chisolm A, Spaits MS, Lim PN, Cesarone G, Khavin I, Tliba O, Amrani Y, Panettieri RA Jr, Krymskaya VP.

Mol Pharmacol. 2008 Mar;73(3):778-88. Epub 2007 Dec 19.

3.

Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2.

Goncharova EA, Goncharov DA, Spaits M, Noonan DJ, Talovskaya E, Eszterhas A, Krymskaya VP.

Am J Respir Cell Mol Biol. 2006 May;34(5):561-72. Epub 2006 Jan 19.

4.

Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM).

Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, Walker CL, Noonan D, Kwiatkowski DJ, Chou MM, Panettieri RA Jr, Krymskaya VP.

J Biol Chem. 2002 Aug 23;277(34):30958-67. Epub 2002 Jun 3.

5.

mTORC2 is required for proliferation and survival of TSC2-null cells.

Goncharova EA, Goncharov DA, Li H, Pimtong W, Lu S, Khavin I, Krymskaya VP.

Mol Cell Biol. 2011 Jun;31(12):2484-98. doi: 10.1128/MCB.01061-10. Epub 2011 Apr 11.

6.
7.

Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).

Goncharova EA, Goncharov DA, Fehrenbach M, Khavin I, Ducka B, Hino O, Colby TV, Merrilees MJ, Haczku A, Albelda SM, Krymskaya VP.

Sci Transl Med. 2012 Oct 3;4(154):154ra134. doi: 10.1126/scitranslmed.3003840.

8.

Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.

Atochina-Vasserman EN, Goncharov DA, Volgina AV, Milavec M, James ML, Krymskaya VP.

Am J Respir Cell Mol Biol. 2013 Nov;49(5):704-9. doi: 10.1165/rcmb.2013-0203RC.

9.

Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.

Makovski V, Jacob-Hirsch J, Gefen-Dor C, Shai B, Ehrlich M, Rechavi G, Kloog Y.

Cell Death Dis. 2014 Dec 4;5:e1557. doi: 10.1038/cddis.2014.502.

10.

Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.

Krymskaya VP.

Proc Am Thorac Soc. 2008 Jan 1;5(1):119-26. Review.

11.

Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.

Li C, Zhang E, Sun Y, Lee PS, Zhan Y, Guo Y, Osorio JC, Rosas IO, Xu KF, Kwiatkowski DJ, Yu JJ.

PLoS One. 2014 Oct 27;9(10):e104809. doi: 10.1371/journal.pone.0104809. eCollection 2014.

12.

Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway.

Fang P, Hwa V, Rosenfeld RG.

Exp Cell Res. 2006 May 1;312(8):1229-39. Epub 2006 Jan 19.

PMID:
16427044
13.

Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.

Lee PS, Tsang SW, Moses MA, Trayes-Gibson Z, Hsiao LL, Jensen R, Squillace R, Kwiatkowski DJ.

Am J Respir Cell Mol Biol. 2010 Feb;42(2):227-34. doi: 10.1165/rcmb.2009-0050OC. Epub 2009 Apr 24.

14.

Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.

Goncharova EA, Krymskaya VP.

J Cell Biochem. 2008 Feb 1;103(2):369-82. Review.

PMID:
17541983
15.

Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.

Grzegorek I, Zuba-Surma E, Chabowski M, Janczak D, Szuba A, Dziegiel P.

Anticancer Res. 2015 Jun;35(6):3341-51.

PMID:
26026094
16.

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.

Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG Jr.

Genes Dev. 2004 Dec 1;18(23):2893-904. Epub 2004 Nov 15.

17.

Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.

Sun Y, Gallacchi D, Zhang EY, Reynolds SB, Robinson L, Malinowska IA, Chiou TT, Pereira AM, Li C, Kwiatkowski DJ, Lee PS, Yu JJ.

Am J Respir Cell Mol Biol. 2014 Dec;51(6):738-49. doi: 10.1165/rcmb.2014-0033OC.

18.

Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.

Atochina-Vasserman EN, Abramova E, James ML, Rue R, Liu AY, Ersumo NT, Guo CJ, Gow AJ, Krymskaya VP.

Am J Physiol Lung Cell Mol Physiol. 2015 Dec 15;309(12):L1447-54. doi: 10.1152/ajplung.00262.2015. Epub 2015 Oct 2.

19.

Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas.

Robb VA, Astrinidis A, Henske EP.

Mod Pathol. 2006 Jun;19(6):839-46. Erratum in: Mod Pathol. 2006 Jun;19(6):889.

20.

Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis.

Goncharova EA, Goncharov DA, Lim PN, Noonan D, Krymskaya VP.

Am J Respir Cell Mol Biol. 2006 Apr;34(4):473-80. Epub 2005 Dec 30.

Supplemental Content

Support Center